The Fall COVID19 Booster is a PUBLIC HEALTH FIASCO - It has no clinical evidence| Total Scam
What this video covers
In one of his most-watched solo episodes, Dr. Vinay Prasad takes aim at the fall 2023 COVID-19 booster campaign — the updated monovalent XBB.1.5 formulation recommended broadly to Americans. The video is built from two of his Substack essays, and its thesis is in the title: Prasad argues the booster was authorized and recommended without any randomized clinical evidence that it reduces illness, hospitalization, or death.
Prasad’s core evidentiary claim is that the FDA authorized the updated formula based on immunobridging — antibody measurements from a small study of roughly 50 people — rather than a randomized trial with clinical endpoints. He contrasts this with the original vaccine trials, which did measure symptomatic infection, and argues that recommending a product to tens of millions of people, including young, healthy, previously infected Americans, on antibody data alone was a collapse of evidentiary standards.
He further argues the public health messaging oversold the shot: officials implied broad benefit while the data could not tell any individual, especially a young healthy person, what they would gain. The “fiasco” and “scam” framing reflects his view that the campaign was driven by institutional momentum and manufacturer interests rather than science — a theme that would later define his tenure as FDA’s vaccine chief, where he pushed to require clinical-outcome trials for updated vaccines in younger, healthy populations.
Key points
- Prasad argues the fall 2023 XBB.1.5 booster was authorized on immunobridging data — antibody levels from roughly 50 study participants — with no randomized trial measuring clinical outcomes like symptomatic infection, hospitalization, or death.
- He contends this was a sharp departure from the original COVID vaccine authorizations, which rested on large randomized trials with clinical endpoints.
- According to Prasad, recommending the booster broadly — including to young, healthy, and previously infected people — could not be justified because the evidence base said nothing about what those groups would gain.
- He criticizes public health officials for messaging that implied broad, certain benefit, arguing the honest message was that individual benefit for most recipients was unknown.
- Prasad frames the campaign as institutional inertia plus commercial interest, arguing the policy served manufacturers’ sales more than the public’s health.
- He connects the episode to his wider evidence-based-medicine argument: surrogate endpoints (antibodies) are not clinical outcomes, and regulators should not treat them as equivalent.
- He states his personal position: he will not take another COVID-19 vaccine until a randomized trial shows benefit for someone of his age and health; he would not advise it for healthy people under 65, and would discourage it entirely for anyone under 30.
- He quotes a pharmaceutical-industry researcher: “first, do no harm… the hypothesis should be tested in a company funded randomized trial,” and cites Peter Doshi’s BMJ essay arguing flu-vaccine uptake is driven by marketing on a weak evidence base.
The video also states his personal position plainly: he says he will never receive another COVID-19 vaccine until a randomized trial shows someone of his age and health benefits from it; he would not advise anyone healthy under 65 to take it — in line with the UK’s approach — and he would discourage all COVID vaccination in anyone under 30. He reads a quote from a doctor working in pharmaceutical drug development, who wrote: “first, do no harm: a medical intervention should be recommended only with clear evidence that benefit outweighs possible harm… the hypothesis should be tested in a company funded randomized trial.” On the flu-shot comparison, he cites Peter Doshi’s BMJ essay on marketing the flu vaccine and Cochrane reviews showing modest, uncertain effectiveness — arguing the flu shot also needs more randomized trials, but that this does not excuse the COVID booster’s weaker base.
- Context: FDA and CDC officials at the time said immunobridging was an appropriate standard for strain updates — analogous to annual flu shots — and that waiting for full clinical trials would delay protection against circulating variants. Prasad rejects that analogy.